Nipradolol

Cat. No.: HY-106523 CAS No.: 81486-22-8 Molecular Formula: $C_{15}H_{22}N_2O_6$ Molecular Weight: 326.34

Target: Adrenergic Receptor

Pathway: GPCR/G Protein; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

Product Data Sheet

BIOLOGICAL ACTIVITY

Description	Nipradolol (KT-210; K-351) is a potent blocker of alpha-1-adrenergic receptors. Nipradolol inhibits the increase of intraocular pressure (IOP) in an albino rabbit model induced by Phenylephrine (HY-B0769). Nipradolo suppresses the noradrenaline (NA)-induced muscles contraction, also exhibits vasodilator activity on the dog coronary artery ^{[1][2]} .
IC ₅₀ & Target	α1-adrenergic receptor
In Vitro	Nipradolol (1 μ M; 10 min) inhibits K-induced contraction in dog muscles with an ID ₅₀ value of 0.8 μ M ^[1] . Nipradolol (1 μ M; 10 min) reduces the resting tone and to suppress the NA-induced contraction in proximal region ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Nipradolol (0.125%, 0.25%, 0.5%; I.V.; single dose) inhibits the increase in IOP in a concentration-dependent manner on rabbits' eyes ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. 3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran (K-351) and its denitrated derivative on smooth muscle cells of the dog coronary artery. Br J Pharmacol. 1983 May;79(1):285-95.

[2]. Nishio K. Alpha-1-adrenoceptor blocking activity of KT-210 (nipradilol ophthalmic solution) on intraocular pressure in the rabbit eye[J]. Nihon Ganka Kiyo (Folia Ophthalmol Jpn), 1999, 50: 655-660.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA